Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes

Aschner, 1999, Glial cells in neurotoxicity development, Annu. Rev. Pharmacol. Toxicol., 39, 151, 10.1146/annurev.pharmtox.39.1.151

Banati, 1993, Cytotoxicity of microglia, Glia, 7, 111, 10.1002/glia.440070117

Barres, 2000, Neuronal and glial cell biology, Curr. Opin. Neurobiol., 10, 642, 10.1016/S0959-4388(00)00134-3

Bruce-Keller, 1999, Microglial–neuronal interactions in synaptic damage and recovery, J. Neurosci. Res., 58, 191, 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E

Cacabelos, 1994, Brain interleukin-1 beta in Alzheimer's disease and vascular dementia, Methods Find Exp. Clin Pharmacol., 16, 141

Campos, 1994, Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse, Endocrinology, 134, 2156, 10.1210/endo.134.5.8156917

Chao, 1995, Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-d-aspartate receptors, Brain Behav. Immun., 9, 355, 10.1006/brbi.1995.1033

Chung, 1990, Tumor necrosis factor-alpha production by astrocytes: induction by lipopolysaccharide, IFN-gamma, and IL-1 beta, J. Immunol., 144, 2999, 10.4049/jimmunol.144.8.2999

Delgado, 1998, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-κB and cAMP response element-binding protein/c-Jun, J. Biol. Chem., 273, 31427, 10.1074/jbc.273.47.31427

Göke, 1995, Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites, Eur. J. Neurosci., 7, 2294, 10.1111/j.1460-9568.1995.tb00650.x

Gonzalez, 1989, A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence, Nature, 337, 749, 10.1038/337749a0

Griffin, 2002, Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease, J. Leukoc. Biol., 72, 233, 10.1189/jlb.72.2.233

Iwai, 2000, Effects of glucagon-like peptide-1 on LTP in β-amyloid protein (1–42)-treated hippocampal slices, Soc. Neurosci. Abstr., 26, 1116

Jhala, 2003, cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2, Genes Dev., 17, 1575, 10.1101/gad.1097103

Kalla, 2003, Loss of microglial ramification in microglia-astrocyte cocultures: involvement of adenylate cyclase, calcium, phosphatase, and Gi-protein systems, Glia, 41, 50, 10.1002/glia.10176

Kielian, 2004, Immunopathogenesis of brain abscess, J. Neuroinflamm., 1, 16, 10.1186/1742-2094-1-16

Loddick, 1996, Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat, J. Cereb. Blood Flow Metab., 16, 932, 10.1097/00004647-199609000-00017

Masters, 1985, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc. Natl. Acad Sci. U.S.A., 82, 4245, 10.1073/pnas.82.12.4245

McGeer, 1989, Immune response in Alzheimer's disease, Can. J. Neurol. Sci., 16, 516, 10.1017/S0317167100029863

Merchenthaler, 1999, Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system, J. Comp. Neurol., 403, 261, 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5

Mojsov, 1986, Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing, J. Biol. Chem., 261, 11880, 10.1016/S0021-9258(18)67324-7

Monje, 2003, Inflammatory blockade restores adult hippocampal neurogenesis, Science, 302, 1760, 10.1126/science.1088417

Mrak, 2001, Interleukin-1, neuroinflammation, and Alzheimer's disease, Neurobiol. Aging, 22, 903, 10.1016/S0197-4580(01)00287-1

Oka, 1999, Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus, Neuroreport, 10, 1643, 10.1097/00001756-199906030-00004

Oka, 1999, Endogenous GLP-1 modulates hippocampal activity in β-amyloid protein-treated rats, Neuroreport, 10, 2961, 10.1097/00001756-199909290-00016

Oka, 1862, Behavioral studies indicate a role for glucagon-like peptide-1 in memory and learning in rat, Soc. Neurosci. Abstr., 25

Oka, 2000, Endogenous GLP-1 is involved in β-amyloid protein-induced memory impairment and hippocampal neuronal death in rats, Brain Res., 878, 194, 10.1016/S0006-8993(00)02741-4

Perez, 1999, Transcriptional regulation of the interleukin-1β promoter via fibrinogen engagement of the CD18 integrin receptor, Am. J. Respir. Cell Mol. Biol., 20, 1059, 10.1165/ajrcmb.20.5.3281

Stewart, 1997, Risk of Alzheimer's disease and duration of NSAID use, Neurology, 48, 626, 10.1212/WNL.48.3.626

Yada, 1993, Glucagon-like peptide-1-(7–36)amide and a rise in cyclic adenosine 3′,5′-monophosphate increase cytosolic free Ca2+ in rat pancreatic β-cells by enhancing Ca2+ channel activity, Endocrinology, 133, 1685, 10.1210/endo.133.4.8404610

Yamasaki, 1995, Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats, Stroke, 26, 676, 10.1161/01.STR.26.4.676